Ashland Inc.
GENERAL
Ashland Inc. is a global additives and specialty ingredients company with a conscious and proactive mindset for sustainability. Our common stock is listed on the New York Stock Exchange (“NYSE”) under the ticker symbol “ASH”. The terms “Ashland,” the “Company,” “we” and “our” used herein refer to Ashland Inc., a Delaware corporation, and its predecessors, and its consolidated subsidiaries, except where the context indicates otherwise.
The Company serves customers in a wide range of consumer and industrial markets including, architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. With approximately 2,800 employees worldwide, Ashland serves customers in more than 100 countries.
Ashland’s reportable operating segments ("reportable segments") include: Life Sciences, Personal Care, Specialty Additives and Intermediates. Unallocated and other includes corporate governance activities and certain legacy matters.
Life Sciences is composed of pharmaceuticals, nutrition, agricultural chemicals, diagnostic films (formerly known as advanced materials). Pharmaceutical solutions include controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers and tablet binders, and formulation-enabling technologies used in oral, injectable, biologic, and advanced therapeutic drug formulations. The portfolio also includes bioprocessing chemicals that support the development and manufacture of biologics, vaccines, and other therapeutic products. Nutrition solutions include thickeners, stabilizers, emulsifiers and additives for enhancing mouthfeel, controlling moisture migration, reducing oil uptake and binding structured foods. Agricultural chemicals solutions include specialty polymers, bio-based technologies, dispersants, and formulation aids that improve the performance, stability, delivery, and application of crop protection products, biologicals, seed treatments, and other agricultural formulations. Customers include pharmaceutical, food and beverage manufacturers, hospitals and radiologists. The nutraceuticals business was sold in August 2024.
Personal Care is composed of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household solutions. These businesses have a broad range of natural, nature-derived, biodegradable, and high-performance ingredients for customer-driven solutions to help protect, renew, moisturize and revitalize skin and hair, and provide solutions for toothpastes, mouth washes and rinses, denture cleaning and care for teeth. Personal Care supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers for household, industrial and institutional cleaning products. Customers include formulators at large multinational branded consumer products companies and smaller, independent boutique companies. The Avoca business was sold in March 2025.
Specialty Additives is composed of rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive and various industrial markets. Solutions include coatings additives for architectural paints, finishes and lacquers, cement- and gypsum-based dry mortars, ready-mixed joint compounds, synthetic plasters for commercial and residential construction, and specialty materials for industrial
3
applications. Products include rheology modifiers (cellulosic and associative thickeners), foam control agents, surfactants and wetting agents, pH neutralizers and environmental filters, ingredients that aid the manufacturing process of ceramic capacitors, advanced ceramics used in catalytic converters, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals and alloys for welding. Products help improve desired functional outcomes through rheology modification and control, water retention, workability, adhesive strength, binding power, film formation, deposition and suspension and emulsification. Customers include, but are not limited to, global paint manufacturers, electronics and automotive manufacturers, textile mills, the construction industry and welders.
Intermediates is composed of the production of 1,4 butanediol ("BDO") and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, agriculture, pharmaceuticals, water filtration membranes and more. BDO is also supplied to Life Sciences, Personal Care, and Specialty Additives reportable segments for use as a raw material.
Unallocated and Other generally includes items such as certain significant company-wide restructuring activities, corporate governance costs and legacy costs or activities that relate to divested businesses that are no longer operated by Ashland.
Available Information -
Our principal executive offices are located at 8145 Blazer Drive, Wilmington, Delaware 19808.
On the Investor Relations section of our website, www.ashland.com, you may obtain additional information about us, free of charge, including:
We also provide printed copies of any of these documents to any stockholder free of charge upon request. The SEC also maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information that is filed electronically with the SEC.
LIFE SCIENCES
Life Sciences is a leading supplier of excipients, formulation technologies, and tablet coating systems serving the pharmaceutical, nutrition industries, agricultural chemicals, and diagnostic films.
4
Its pharmaceutical portfolio includes a comprehensive range of polymers and functional excipients used as tablet binders, super disintegrants, sustained-release agents and drug solubilizers, as well as coating systems for immediate, delayed, and sustained-release applications. The portfolio also includes excipients and formulation-enabling technologies used in injectable, biologic, and advanced therapeutic drug formulations to improve solubility, bioavailability, stability, manufacturability, and product performance. In addition, the Life Sciences portfolio provides specialty materials used in bioprocessing applications supporting the development and manufacture of biologics, vaccines, and other therapeutic products. Core pharmaceutical products include cellulosics and vinyl pyrrolidone polymers which are used primarily in oral solid dosage drug formulations.
Its nutrition portfolio provides functional benefits in areas such as thickening, texture control, thermal gelation, structure enhancement, water binding, clarification, and stabilization. Its core products include cellulose gums and vinyl pyrrolidone polymers which are used in a wide range of offerings for bakery, beverage, dairy, desserts, meat products, pet food, prepared foods, sauces and savory products.
Its agricultural chemicals portfolio provides formulation technologies and specialty ingredients that enhance the performance, stability, and delivery of crop protection products, seed treatments, biologicals, and other agricultural formulations. Core products include functional polymers, bio-based technologies, and formulation aids used to improve dispersion, suspension, adhesion, compatibility, and application performance.
Life Science markets and distributes its products across the Americas, Europe, the Middle East, Africa and Asia Pacific. It serves its end markets through 10 manufacturing facilities and 10 laboratory facilities, which may share sites and therefore do not necessarily represent 20 distinct locations. Its US facilities are located in Texas City, Texas; Calvert City, Kentucky; Columbus, Ohio; Bridgewater, New Jersey, and Wilmington, Delaware; and internationally in Brazil; Belgium, China; France, Germany; India; Ireland; Mexico; Netherlands, Thailand; and Turkey.
For the year ended September 30, 2026, the following Life Sciences product categories were 10% or greater of Ashland’s total consolidated sales:
Product |
% of Life Sciences sales |
% of Ashland total consolidated sales |
Cellulosics |
47% |
40% |
Polyvinylpyrrolidones ("PVP") |
39% |
24% |
PERSONAL CARE
The Personal Care portfolio of oral care products delivers active ingredients in toothpaste and mouthwashes; provides bioadhesive functionality for dentures; delivers flavor, texture and other functional properties; and provides product binding to ensure form and function throughout product lifecycle.
Loading financial statements...
Financial statements
data from SEC XBRL filings. Values are as-reported; restatements supersede originals. Values reported in .
| Line item |
|---|
| Period ending |
See Management’s Discussion and Analysis of Financial Condition and Results of Operations on pages M-1 through M-53.
Next expected filings
- ~2027-02-02 10-Q expected by 2027-02-11 (in 72 days)
- ~2027-04-28 10-Q expected by 2027-05-07 (in 157 days)
- ~2027-07-28 10-Q expected by 2027-08-06 (in 248 days)
- ~2027-11-19 10-K expected by 2027-11-28 (in 362 days)
Predicted from historical filing cadence; not an SEC commitment.
Recent SEC filings
- 2026-11-20 10-K Annual Report
- 2026-11-03 8-K Earnings Release; Regulation FD Disclosure; Financial Statements and Exhibits
- 2026-09-25 8-K Material Agreement Entered; Material Financial Obligation; Financial Statements and Exhibits
- 2026-08-10 8-K/A Officer/Director Change
- 2026-07-31 8-K Material Agreement Entered; Material Financial Obligation; Financial Statements and Exhibits
- 2026-07-29 10-Q Quarterly Report
- 2026-07-28 8-K Material Agreement Entered; Officer/Director Change; Regulation FD Disclosure
- 2026-07-28 8-K Earnings Release; Regulation FD Disclosure; Financial Statements and Exhibits
- 2026-05-29 8-K Material Agreement Entered; Material Financial Obligation; Financial Statements and Exhibits
- 2026-05-18 8-K Officer/Director Change; Financial Statements and Exhibits
- 2026-04-29 10-Q Quarterly Report
- 2026-04-28 8-K Earnings Release; Regulation FD Disclosure; Financial Statements and Exhibits
- 2026-02-03 10-Q Quarterly Report
- 2026-02-02 8-K Earnings Release; Regulation FD Disclosure; Financial Statements and Exhibits
- 2026-01-27 8-K Officer/Director Change; Financial Statements and Exhibits